SAT0340 CHARACTERIZATION OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS BY PRESENCE OF ENTHESITIS: DATA FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY

Background Enthesitisis a common extra-axial manifestation in patients with axial spondyloarthritis(AxSpA) 1,2 ; however, not much is known about the prevalence of enthesitisin AxSpA and its impact on disease burden in US real-world settings. Objectives This study describes characteristics of patients with AxSpA who had enthesitisvs patients without enthesitis. Methods This study included patients aged ≥ 18 years with AxSpA enrolled in the Corrona PsA/SpA Registry between March 2013 and August 2018. Enthesitisat enrollment was assessed via the Spondyloarthritis Research Consortium of Canada (SPARCC) EnthesitisIndex. Patient demographics, clinical characteristics, treatment profiles, disease activity, quality of life, and work productivity were compared between patients with and without enthesitisusing t tests or Wilcoxon rank-sum tests for continuous variables and χ 2 or Fisher’s exact tests for categorical variables. Results Of 477 patients with AxSpA, 121 (25.4%) had enthesitis. Symptom and disease duration were similar between patients with and without enthesitis. In patients with enthesitis, a higher proportion were female, were more likely to have non-radiographic AxSpA and a historyof depression, serious infections, and fibromyalgia vs those without enthesitis(all P Table 1 ). Current treatment with biologics or conventional synthetic disease-modifying antirheumatic drug(csDMARD) monotherapy was similar regardless of presence of enthesitis; however, patients with enthesitiswere more likely to have prior csDMARD and biologic use, as well as current methotrexate use. Patients with enthesitishad worse disease activity (ASDAS, BASDAI, and BASFIscores; tender and swollen joint counts; physician global assessment; and DAPSA and cDAPSA scores), spinal mobility measures, quality of life (pain, fatigue, HAQ scores, and EQ VAS scores), and greater work impairment than patients without enthesitis(all P Table 2 ). Conclusion Among patients with AxSpA in this US real-world study, the presence of enthesitiswas associated with worse disease activity and quality of life compared to patients without enthesitis. References [1] Nadon V, et al. Clin Exp Rheumatol. 2018Dec19 [Epub ahead of print]. [2] de Winter JJ, et al. Arthritis Res Ther. 2016;18(1):196. Acknowledgement This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Novartis, with financial support provided by Novartis. Disclosure of Interests Philip J Mease Grant/research support from: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Consultant for: AbbVie, Amgen, BMS, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Speakers bureau: AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer and UCB, Mei Liu Employee of: M. Liu is an employee of Corrona, LLC., Sabrina Rebello Employee of: Corrona, LLC, Winnie Hua Employee of: W. Hua is an employee of Corrona, LLC., Robert McLean: None declared, Esther Yi Consultant for: E. Yi is a postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health, providing services to Novartis Pharmaceuticals Corporation., Yujin Park Employee of: Y. Park is an employee of Novartis., Alexis Ogdie Grant/research support from: (To my university) Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Consultant for: AbbVie, Bristol-MyersSquibb, Celgene, Corrona, Eli Lilly and Company, Novartis, Pfizer, and Takeda, Consultant for: AbbVie, Amgen, Bristol-MyersSquibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda